Cargando…

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis

BACKGROUND: The role of capecitabine in neoadjuvant and adjuvant chemotherapy for early-stage triple-negative breast cancer (TNBC) is highly controversial. Our meta-analysis was designed to further elucidate the effects of capecitabine on survival in early-stage TNBC patients and its safety. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huo, Xingfa, Li, Jinming, Zhao, Fuxing, Ren, Dengfeng, Ahmad, Raees, Yuan, Xinyue, Du, Feng, Zhao, Jiuda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816481/ https://www.ncbi.nlm.nih.gov/pubmed/33468087 http://dx.doi.org/10.1186/s12885-021-07791-y

Ejemplares similares

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Xin, Yuanfang, et al.
Publicado: (2021)

Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis
por: Li, Jinming, et al.
Publicado: (2020)

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
por: Shen, Guoshuang, et al.
Publicado: (2021)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis
por: Huo, Xingfa, et al.
Publicado: (2023)

Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Fuxing, et al.
Publicado: (2021)

A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis
por: Guo, Xinjian, et al.
Publicado: (2019)

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
por: de Boo, Leonora W., et al.
Publicado: (2022)

Elevated expression of TUBA1C in breast cancer predicts poor prognosis
por: Zhao, Yi, et al.
Publicado: (2023)

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
por: Shen, Guoshuang, et al.
Publicado: (2018)

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
por: Bai, Jie, et al.
Publicado: (2023)

The Effect of Neoadjuvant vs Adjuvant Chemotherapy on Final Outcome of Patients with Triple Negative Breast Cancer
por: Dabbagh, Najmeh, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
por: Lluch, Ana, et al.
Publicado: (2020)

Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials
por: Li, Zhiyang, et al.
Publicado: (2022)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zhang, Zilin, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
por: Di Lisa, Francesca Sofia, et al.
Publicado: (2023)

A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients
por: Zheng, Tianzhi, et al.
Publicado: (2019)

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
por: Asleh, Karama, et al.
Publicado: (2023)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
por: Xia, Lin-Yu, et al.
Publicado: (2020)

Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
por: Bagegni, Nusayba A., et al.
Publicado: (2019)

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
por: Dieci, Maria Vittoria, et al.
Publicado: (2021)

Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy
por: Zhao, Yanding, et al.
Publicado: (2020)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
por: Tian, Wentao, et al.
Publicado: (2023)

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
por: Huang, Min, et al.
Publicado: (2023)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer
por: Biswas, Tithi, et al.
Publicado: (2017)

Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy
por: Cho, Jang Ho, et al.
Publicado: (2017)

TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study
por: Inoue, Kenichi, et al.
Publicado: (2019)

The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
por: Mousavi, Seyyed AsadoLah, et al.
Publicado: (2013)

Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer
por: Guo, Qiusheng, et al.
Publicado: (2023)

Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
por: Li, Yi-Hui, et al.
Publicado: (2018)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_54q23vn3iur6sb83urlq4ts2dh